Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Set the hook $$$$$$ reel steady $$
What kind of merger that I don’t get it where is benefit here You are getting %3 what ? New stock or how much worth it Ktra now Still 5 millions One things can be true ktra may be going to bankrupt Now safe But I never buy stock merger %3 to %97 this is not merger I don’t know what is that ?maybe something going on here Look at the stock price Noting going on here
What kind of merger that I don’t get it where is benefit here You are getting %3 what ? New stock or how much worth it Ktra now Still 5 millions One things can be true ktra may be going to bankrupt Now safe But I never buy stock merger %3 to %97 this is not merger I don’t know what is that ?maybe something going on here Look at the stock price Noting going on here
meh, im done, seen enough.
The dip is in, let’s ripp baby!!!!
Blow the short rats out of their holes dude!!!
KTRA: Sounds fine to me, Dude!!
A VACCINE FOR CANCER IS ONE OF THE MOST OUTRAGEOUS THINGS I'VE EVER HEARD...CANCER IS A MITOCHONDRIAL DISEASE...OH WAIT...A VACCINE CAN'T STOP A COLD OR FLU....BUT STOP CANCER....ANYTHING FOR THE CROOKS TO DUMP SHARES AND POCKET THE CASH ON THE HANDS OF THE STUPID!
Let the line out $$$$$
If it is true this will be exciting
Interesting post on other board
Alerted the 8K is all......some go down.......most go up........
Z
I got in on the dip, im hopeful.
It went from 24c 14c does your scanner need batteries
Helluva nice day today..........I guess time will tell...........
Z
$KTRA phase 3 cancer vaccine? What do you think the potential is here?
FDA Approval will blow the roof off this baby
Lots of eyes new blood in the house
Whales coming in for the kill
massive bid just showed up at…
..
6:06pm e/t but was “outbid” by another higher bid. but looking good!!
moving up now, lets do this!!
Yep, & that was too late, for all intents & purposes.
I SAW IT WHEN IT WAS 1700%. I MISSED 'VERBW" LAST 2 WEEKS 2600%. WILL NOT MISS THE NEXT "W' PLAY. KEEP ME INFORMED ON TIME. THANK U ALWAYS
The WARRANTS only, but only scored barely $900 --- fast-draw, Western style!! (Saw its Parent Firm suddenly POP-UP on Fidelity's "MARKET MOVERS" list.)
you caught some of 'BROGW'*******
Over $32,000,000 MILLION DOLLARS in shares traded so far today!!! Big news AF?!!!
bottom may have been found here… perfect time to enter!!!!!!
Reversal$$$$$$$$
The dip is in dudes!!!! Get ready to rippp$$
hi meta! nice to see you again!
Got to burn the short rats ass
New blood soaking up the float violent move is coming,
from past runs, i see dollars are truly possible here.
Crystal ball glowing 1$ Green AH
Blue skies baby!!!!
you are right about that.
grabbed some on the dip.
KTRA....................................https://stockcharts.com/h-sc/ui?s=KTRA&p=W&b=5&g=0&id=p86431144783
KTRA: Song break for my (languishing) KTRA shares, which is dedicated to the KTRA CEO!!! (One of the most UNUSUAL rock songs of all time!!!)
KTRA: Hey, Bro, if @BROG --- & especially the @BROGW (Warrants) --- can SOAR like they are doing today, despite getting SUED & INVESTIGATED all over the place!!! Then why can't the same happen for KTRA too, eventually???
Followers
|
61
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
1402
|
Created
|
01/25/13
|
Type
|
Free
|
Moderators |
https://www.kintara.com/
Kintara Therapeutics is focused on developing unique anti-cancer compounds, supported by a strong scientific rationale for development in indications with established biomarkers, and where patients are failing, or are unable to tolerate, current therapies.
VAL-083 is a "first-in-class" small molecule chemotherapeutic. Its unique structure provides many valuable benefits, including the targeting of DNA for its therapeutic effect and its ability to cross the blood brain barrier, critical for activity against central nervous system (CNS) tumors.
VAL-083 has completed Pre-Clinical, Phase I and II trials for the treatment of bevacizumab-refractory glioblastoma multiforme (GBM) and is currently being studied in two Phase II biomarker-driven clinical trials for unmethylated-MGMT GBM.
We are also pursuing the development of VAL-083 in the treatment of ovarian cancer.
REM-001 has broad utility for the treatment of serious cutaneous oncology indications. REM-001 has been previously studied in four Phase 2 and/or Phase 3 clinical trials in patients with cutaneous metastatic breast cancer (“CMBC”), who had previously received chemotherapy and/or failed radiation therapy.
Zacks Small-Cap Research
https://s27.q4cdn.com/906368049/files/News/2021/Zacks_SCR_Research_10112021_KTRA_Vandermosten.pdf
Based on our DCF model and a 15% discount rate, Kintara Therapeutics is valued at approximately $5.25 per share. Our model applies a 60% probability for VAL-083 in unmethylated GBM, a 50% probability in methylated GBM and a 50% probability of approval and commercialization in REM-001 for CMBC. The model includes contributions from the United States and Europe. Other regions will be included upon further clarity.
Shares Outstanding (mil) 43.2
Current Price (10/8/2021) $0.77
Valuation $5.25.
11/03/21
Thanks to its promising pipeline and $0.88 share price, 5-star analyst Michael King, of
H.C. Wainwright, sees an attractive entry point for investors.
“We are bullish about KTRA shares for the following five reasons
: (1) The GBM AGILE trial tests VAL-083 in
all three subtypes of GBM, allowing for multiple opportunities for VAL-083 to prove its
efficacy against phenotypically distinct types of the disease.
(2) VAL-083 is a bifunctional
alkylating agent that crosses the blood brain barrier and exhibits very favorable pharmacologic
properties relative TMZ; fulfilling the need for systemic availability in the brain.
(3) VAL-083
has an established favorable safety record, both from initial trials and prior clinical use in
multiple indications.
(4) Dire unmet need in GBM may present relatively low bar for approval.
(5) Phase 3 ready REM-001 is an additional bonus which is not factored into our valuation
assumptions and could potentially deliver value to shareholders while providing a backstop
against downside,” King explained.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |